KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Cash from Operations: 2015-2025

Historic Cash from Operations for BeOne Medicines (ONC) over the last 11 years, with Sep 2025 value amounting to $402.6 million.

  • BeOne Medicines' Cash from Operations rose 113.70% to $402.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $785.4 million, marking a year-over-year increase of 279.55%. This contributed to the annual value of -$140.6 million for FY2024, which is 87.85% up from last year.
  • BeOne Medicines' Cash from Operations amounted to $402.6 million in Q3 2025, which was up 52.71% from $263.6 million recorded in Q2 2025.
  • In the past 5 years, BeOne Medicines' Cash from Operations ranged from a high of $402.6 million in Q3 2025 and a low of -$563.8 million during Q1 2023.
  • Moreover, its 3-year median value for Cash from Operations was -$78.2 million (2023), whereas its average is -$53.4 million.
  • As far as peak fluctuations go, BeOne Medicines' Cash from Operations plummeted by 350.36% in 2022, and later soared by 375.76% in 2025.
  • Over the past 5 years, BeOne Medicines' Cash from Operations (Quarterly) stood at $127.1 million in 2021, then slumped by 350.36% to -$318.2 million in 2022, then surged by 30.34% to -$221.6 million in 2023, then spiked by 133.91% to $75.2 million in 2024, then spiked by 113.70% to $402.6 million in 2025.
  • Its last three reported values are $402.6 million in Q3 2025, $263.6 million for Q2 2025, and $44.1 million during Q1 2025.